Skip to main content
Erschienen in: World Journal of Urology 1/2010

01.02.2010 | Topic Paper

Thulium laser enucleation of the prostate (ThuLEP): transurethral anatomical prostatectomy with laser support. Introduction of a novel technique for the treatment of benign prostatic obstruction

verfasst von: Thomas R. W. Herrmann, T. Bach, F. Imkamp, A. Georgiou, M. Burchardt, M. Oelke, A. J. Gross

Erschienen in: World Journal of Urology | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

Transurethral removal of prostatic tissue is the treatment choice for benign prostatic enlargement and benign prostatic obstruction. Urodynamic results are directly linked to the amount of removed tissue which, however, is directly associated with intra- and postoperative morbidity. Transurethral laser operations of the prostate offer the advantage of decreased bleeding complications and the possibility to treat patients with bleeding disorders or anticoagulative treatment. The aim of the article is to present a novel technique of complete transurethral removal of the transition zone (enucleation) with the support of the Thulium laser to combine complete anatomical enucleation and maximum urodynamic efficacy with minimal side-effects.

Materials and methods

We present five distinct surgical steps for transurethral complete removal of the transition zone of the prostate (Thulium laser enucleation of the prostate, ThuLEP). Surgical steps are presented in chronological order with the help of intraoperative pictures. Laser energy of 70–90 W is only used for the incision at the verumontanum and bladder neck for removal of the middle lobe, whereas laser energy of 30 W was only used for coagulation of small vessel crossing the surgical capsule towards the transition zone and bladder neck for dissection of the lateral lobes. The lobes themselves are liberated by blunt dissection.

Conclusions

ThuLEP offers complete removal of the transition zone no matter what prostatic size. The techniques combine maximum efficacy with minimal side-effects. Clinical results comparing ThuLEP with open prostatectomy or transurethral resection are awaited.
Literatur
1.
Zurück zum Zitat Herrmann TR, Georgiou A, Bach T, Gross AJ, Oelke M (2009) Laser treatments of the prostate vs TURP/open prostatectomy: systematic review of urodynamic data. Minerva Urol Nefrol 61(3):309–324PubMed Herrmann TR, Georgiou A, Bach T, Gross AJ, Oelke M (2009) Laser treatments of the prostate vs TURP/open prostatectomy: systematic review of urodynamic data. Minerva Urol Nefrol 61(3):309–324PubMed
2.
Zurück zum Zitat Tan AH, Gilling PJ, Kennett KM et al (2003) A randomized trial comparing holmium laser enucleation of the prostate with transurethral resection of the prostate for the treatment of bladder outlet obstruction secondary to benign prostatic hyperplasia in large glands (40 to 200 grams). J Urol 170:1270CrossRefPubMed Tan AH, Gilling PJ, Kennett KM et al (2003) A randomized trial comparing holmium laser enucleation of the prostate with transurethral resection of the prostate for the treatment of bladder outlet obstruction secondary to benign prostatic hyperplasia in large glands (40 to 200 grams). J Urol 170:1270CrossRefPubMed
3.
Zurück zum Zitat Fried NM, Murray KE (2005) High-power thulium fiber laser ablation of urinary tissues at 1.94 microm. J Endourol 19(1):25–31CrossRefPubMed Fried NM, Murray KE (2005) High-power thulium fiber laser ablation of urinary tissues at 1.94 microm. J Endourol 19(1):25–31CrossRefPubMed
4.
Zurück zum Zitat Bach T, Wezel F, Haecker A, Gross AJ, Michel MS (2009) 70 vs 120 W thulium:yttrium-aluminiumgarnet 2 m continuous-wave laser for the treatment of benign prostatic hyperplasia: a systematic ex-vivo evaluation. BJU [Epub ahead of print]. doi: 10.1111/j.1464-410X.2009.09059.x Bach T, Wezel F, Haecker A, Gross AJ, Michel MS (2009) 70 vs 120 W thulium:yttrium-aluminiumgarnet 2 m continuous-wave laser for the treatment of benign prostatic hyperplasia: a systematic ex-vivo evaluation. BJU [Epub ahead of print]. doi: 10.​1111/​j.​1464-410X.​2009.​09059.​x
5.
Zurück zum Zitat Bach T, Herrmann TR, Cellarius C, Gross AJ (2007) Bladder neck incision using a 70 W 2 micron continuous wave laser (RevoLix). World J Urol 25(3):263–267CrossRefPubMed Bach T, Herrmann TR, Cellarius C, Gross AJ (2007) Bladder neck incision using a 70 W 2 micron continuous wave laser (RevoLix). World J Urol 25(3):263–267CrossRefPubMed
6.
Zurück zum Zitat Bach T, Herrmann TR, Ganzer R, Gross AJ (2007) RevoLix™ vaporesection of the prostate: initial results after 54 patients with an one-year follow-up. World J Urol 25(3):257–262CrossRefPubMed Bach T, Herrmann TR, Ganzer R, Gross AJ (2007) RevoLix™ vaporesection of the prostate: initial results after 54 patients with an one-year follow-up. World J Urol 25(3):257–262CrossRefPubMed
7.
Zurück zum Zitat Bach T, Herrmann TR, Ganzer R, Blana A, Burchardt M, Gross AJ, Urologe A (2009) Thulium:YAG vaporesection of the prostate: first results. Urologe A 48(5):529–534CrossRefPubMed Bach T, Herrmann TR, Ganzer R, Blana A, Burchardt M, Gross AJ, Urologe A (2009) Thulium:YAG vaporesection of the prostate: first results. Urologe A 48(5):529–534CrossRefPubMed
8.
Zurück zum Zitat Bach T, Wendt-Nordahl G, Michel MS, Herrmann TR, Gross AJ (2009) Feasibility and efficacy of Thulium: YAG laser enucleation (VapoEnucleation) of the prostate. World J Urol 27(4):541–545CrossRefPubMed Bach T, Wendt-Nordahl G, Michel MS, Herrmann TR, Gross AJ (2009) Feasibility and efficacy of Thulium: YAG laser enucleation (VapoEnucleation) of the prostate. World J Urol 27(4):541–545CrossRefPubMed
9.
Zurück zum Zitat Bach T, Herrmann TR, Haecker A, Michel MS, Gross A (2009) Thulium:yttrium-aluminium-garnet laser prostatectomy in men with refractory urinary retention. BJU Int 104(3):361–364CrossRefPubMed Bach T, Herrmann TR, Haecker A, Michel MS, Gross A (2009) Thulium:yttrium-aluminium-garnet laser prostatectomy in men with refractory urinary retention. BJU Int 104(3):361–364CrossRefPubMed
10.
Zurück zum Zitat Bach T, Netsch Ch, Haecker A, Michel MS, Herrmann TRW, Gross AJ (2009) Thulium:YAG laser enucleation (VapoEnucleation) of the prostate: safety and durability during intermediate-term follow-up. World J Urol [Epub ahead of print] Bach T, Netsch Ch, Haecker A, Michel MS, Herrmann TRW, Gross AJ (2009) Thulium:YAG laser enucleation (VapoEnucleation) of the prostate: safety and durability during intermediate-term follow-up. World J Urol [Epub ahead of print]
11.
Zurück zum Zitat Imkamp F, Bach T, Gross AJ, Kuczyk MA, Herrmann TR (2009) ThuLEP—Thulium laser enucleation of the prostate. J Endourol 23(Suppl 1):24 Imkamp F, Bach T, Gross AJ, Kuczyk MA, Herrmann TR (2009) ThuLEP—Thulium laser enucleation of the prostate. J Endourol 23(Suppl 1):24
12.
Zurück zum Zitat McConnel JD, Barry MJ, Bruskewitz RC et al (1994) Benign prostatic hyperplasia: diagnosis and treatment. Clinical Practice Guideline, Number 8. Chapters 10-14. US: Department of Health and Human Services, Public Health Service, Agency for Health Care policy and research McConnel JD, Barry MJ, Bruskewitz RC et al (1994) Benign prostatic hyperplasia: diagnosis and treatment. Clinical Practice Guideline, Number 8. Chapters 10-14. US: Department of Health and Human Services, Public Health Service, Agency for Health Care policy and research
13.
Zurück zum Zitat Reich O, Gratzke C, Bachmann A, Seitz M, Schlenker B, Hermanek P, Lack N, Stief CG (2008) Urology Section of the Bavarian Working Group for Quality Assurance. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. J Urol 180(1):246–249CrossRefPubMed Reich O, Gratzke C, Bachmann A, Seitz M, Schlenker B, Hermanek P, Lack N, Stief CG (2008) Urology Section of the Bavarian Working Group for Quality Assurance. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. J Urol 180(1):246–249CrossRefPubMed
14.
Zurück zum Zitat Holtgrewe HL, Valk WL (1962) Factors influencing the mortality, morbidity of transurethral prostatectomy: a study of 2, 015 cases. J Urol 87:450PubMed Holtgrewe HL, Valk WL (1962) Factors influencing the mortality, morbidity of transurethral prostatectomy: a study of 2, 015 cases. J Urol 87:450PubMed
15.
Zurück zum Zitat Melchior J, Valk WL, Foret JD, Mebust WK (1974) Transurethral prostatectomy: computerized analysis of 2,223 consecutive cases. J Urol 112:634PubMed Melchior J, Valk WL, Foret JD, Mebust WK (1974) Transurethral prostatectomy: computerized analysis of 2,223 consecutive cases. J Urol 112:634PubMed
16.
Zurück zum Zitat Mebust WK, Holtgrewe HL, Cockett AT, Peters PC (1989) Transurethral prostatectomy: immediate and postoperative complications: A cooperative study of 13 participating institutions evaluating 3, 885 patients. J Urol 141:243–247PubMed Mebust WK, Holtgrewe HL, Cockett AT, Peters PC (1989) Transurethral prostatectomy: immediate and postoperative complications: A cooperative study of 13 participating institutions evaluating 3, 885 patients. J Urol 141:243–247PubMed
17.
Zurück zum Zitat Hiraoka Y, Akimoto M (1989) Transurethral enucleation of benign prostatic hyperplasia. J Urol 142(5):1247–1250PubMed Hiraoka Y, Akimoto M (1989) Transurethral enucleation of benign prostatic hyperplasia. J Urol 142(5):1247–1250PubMed
18.
Zurück zum Zitat Fraundorfer MR, Gilling PJ (1998) Holmium:YAG laser enucleation of the prostate combined with mechanical morcellation: preliminary results. Eur Urol 33(1):69–72CrossRefPubMed Fraundorfer MR, Gilling PJ (1998) Holmium:YAG laser enucleation of the prostate combined with mechanical morcellation: preliminary results. Eur Urol 33(1):69–72CrossRefPubMed
19.
Zurück zum Zitat Teichmann HO, Herrmann TR, Bach T (2007) Technical aspects of lasers in urology. World J Urol 25(3):221–225CrossRefPubMed Teichmann HO, Herrmann TR, Bach T (2007) Technical aspects of lasers in urology. World J Urol 25(3):221–225CrossRefPubMed
20.
Zurück zum Zitat Wendt-Nordahl G, Huckele S, Honeck P, Alken P, Knoll T, Michel MS, Häcker A (2008) Systematic evaluation of a recently introduced 2-microm continuous-wave thulium laser for vaporesection of the prostate. J Endourol 22(5):1041–1045CrossRefPubMed Wendt-Nordahl G, Huckele S, Honeck P, Alken P, Knoll T, Michel MS, Häcker A (2008) Systematic evaluation of a recently introduced 2-microm continuous-wave thulium laser for vaporesection of the prostate. J Endourol 22(5):1041–1045CrossRefPubMed
21.
Zurück zum Zitat Wendt-Nordahl G, von Löwenstern K, Honeck P et al (2008) Ex-vivo comparison of bipolar plasma-kinetic vaporization of the prostate to low power and high power Greenlight laser. J Endourol 22(Suppl 1): A19, BR4–14 Wendt-Nordahl G, von Löwenstern K, Honeck P et al (2008) Ex-vivo comparison of bipolar plasma-kinetic vaporization of the prostate to low power and high power Greenlight laser. J Endourol 22(Suppl 1): A19, BR4–14
22.
Zurück zum Zitat Bach T, Wezel F, Haecker A, Gross AJ, Michel MS (2009) 70 vs 120 W thulium:yttrium-aluminiumgarnet 2 m continuous-wave laser for the treatment of benign prostatic hyperplasia: a systematic ex-vivo evaluation. BJU [Epub ahead of print]. doi:10.1111/j.1464-410X.2009.09059.x Bach T, Wezel F, Haecker A, Gross AJ, Michel MS (2009) 70 vs 120 W thulium:yttrium-aluminiumgarnet 2 m continuous-wave laser for the treatment of benign prostatic hyperplasia: a systematic ex-vivo evaluation. BJU [Epub ahead of print]. doi:10.​1111/​j.​1464-410X.​2009.​09059.​x
23.
Zurück zum Zitat El-Hakim A, Elhilali MM (2002) Holmium laser enucleation of the prostate can be taught: the first learning experience. BJU Int 90(9):863–869CrossRefPubMed El-Hakim A, Elhilali MM (2002) Holmium laser enucleation of the prostate can be taught: the first learning experience. BJU Int 90(9):863–869CrossRefPubMed
24.
Zurück zum Zitat Tinmouth WW, Habib E, Kim SC, Kuo RL, Paterson RF, Terry CL, Elhilali M, Lingeman JE (2005) Change in serum prostate specific antigen concentration after holmium laser enucleation of the prostate: a marker for completeness of adenoma resection? J Endourol 19(5):550–554CrossRefPubMed Tinmouth WW, Habib E, Kim SC, Kuo RL, Paterson RF, Terry CL, Elhilali M, Lingeman JE (2005) Change in serum prostate specific antigen concentration after holmium laser enucleation of the prostate: a marker for completeness of adenoma resection? J Endourol 19(5):550–554CrossRefPubMed
25.
Zurück zum Zitat Ozden C, Inal G, Adsan O, Yazici S, Ozturk B, Cetinkaya M (2003) Detection of prostate cancer and changes in prostate-specific antigen (PSA) six months after surgery for benign prostatic hyperplasia in patients with elevated PSA. Urol Int 71:150CrossRefPubMed Ozden C, Inal G, Adsan O, Yazici S, Ozturk B, Cetinkaya M (2003) Detection of prostate cancer and changes in prostate-specific antigen (PSA) six months after surgery for benign prostatic hyperplasia in patients with elevated PSA. Urol Int 71:150CrossRefPubMed
26.
Zurück zum Zitat Aus G, Bergdahl S, Frösing R, Lodding P, Pileblad E, Hugosson J (1996) Reference range of prostatespecific antigen after transurethral resection of the prostate. Urology 47:529CrossRefPubMed Aus G, Bergdahl S, Frösing R, Lodding P, Pileblad E, Hugosson J (1996) Reference range of prostatespecific antigen after transurethral resection of the prostate. Urology 47:529CrossRefPubMed
27.
Zurück zum Zitat Elmansy HM, Elzayat EA, Sampalis JS, Elhilali MM (2009) Prostatic-specific antigen velocity after holmium laser enucleation of the prostate: possible predictor for the assessment of treatment effect durability for benign prostatic hyperplasia and detection of malignancy. Urology 74(5):1105–1110CrossRefPubMed Elmansy HM, Elzayat EA, Sampalis JS, Elhilali MM (2009) Prostatic-specific antigen velocity after holmium laser enucleation of the prostate: possible predictor for the assessment of treatment effect durability for benign prostatic hyperplasia and detection of malignancy. Urology 74(5):1105–1110CrossRefPubMed
28.
Zurück zum Zitat van Iersel MP, Thomas CM, Witjes WP, de Graaf R, de la Rosette JJ, Debruyne FM (1996) Clinical implications of the rise and fall of prostate specific antigen after laser prostatectomy. Br J Urol 78:742PubMed van Iersel MP, Thomas CM, Witjes WP, de Graaf R, de la Rosette JJ, Debruyne FM (1996) Clinical implications of the rise and fall of prostate specific antigen after laser prostatectomy. Br J Urol 78:742PubMed
29.
Zurück zum Zitat Hai MA, Malek RS (2003) Photoselective vaporization of the prostate: Initial experience with a new 80 W KTP laser for the treatment of benign prostatic hyperplasia. J Endourol 17:93CrossRefPubMed Hai MA, Malek RS (2003) Photoselective vaporization of the prostate: Initial experience with a new 80 W KTP laser for the treatment of benign prostatic hyperplasia. J Endourol 17:93CrossRefPubMed
30.
Zurück zum Zitat Te AE, Malloy TR, Stein BS et al (2004) Photoselective vaporization of the prostate for the treatment of benign prostatic hyperplasia: 12-month results from the first United States multicenter prospective trial. J Urol 172:1404CrossRefPubMed Te AE, Malloy TR, Stein BS et al (2004) Photoselective vaporization of the prostate for the treatment of benign prostatic hyperplasia: 12-month results from the first United States multicenter prospective trial. J Urol 172:1404CrossRefPubMed
31.
Zurück zum Zitat Hamann MF, Naumann CM, Seif C, van der Horst C, Jünemann KP, Braun PM (2008) Functional outcome following photoselective vaporisation of the prostate (PVP): urodynamic findings within 12 months follow-up. Eur Urol 54(4):902–907CrossRefPubMed Hamann MF, Naumann CM, Seif C, van der Horst C, Jünemann KP, Braun PM (2008) Functional outcome following photoselective vaporisation of the prostate (PVP): urodynamic findings within 12 months follow-up. Eur Urol 54(4):902–907CrossRefPubMed
32.
Zurück zum Zitat Fu WJ, Hong BF, Yang Y, Zhang X, Gao JP, Zhang L, Wang XX (2009) Vaporesection for managing benign prostatic hyperplasia using a 2-microm continuous-wave laser: a prospective trial with 1-year follow- up. BJU Int 103(3):352–356CrossRefPubMed Fu WJ, Hong BF, Yang Y, Zhang X, Gao JP, Zhang L, Wang XX (2009) Vaporesection for managing benign prostatic hyperplasia using a 2-microm continuous-wave laser: a prospective trial with 1-year follow- up. BJU Int 103(3):352–356CrossRefPubMed
Metadaten
Titel
Thulium laser enucleation of the prostate (ThuLEP): transurethral anatomical prostatectomy with laser support. Introduction of a novel technique for the treatment of benign prostatic obstruction
verfasst von
Thomas R. W. Herrmann
T. Bach
F. Imkamp
A. Georgiou
M. Burchardt
M. Oelke
A. J. Gross
Publikationsdatum
01.02.2010
Verlag
Springer-Verlag
Erschienen in
World Journal of Urology / Ausgabe 1/2010
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-009-0503-0

Weitere Artikel der Ausgabe 1/2010

World Journal of Urology 1/2010 Zur Ausgabe

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.